Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Pathway Genomics

Pathway Genomics IPO

$932.69MM
Series E-1 Valuation, Jan 2016
Register for details
For more details on financing and valuation of private companies similar to Pathway Genomics before its M&A, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Pathway Genomics IPO date and status

2008
Founded
Feb 2020
MA Closed

Company details

Pathway Genomics is a biotechnology company focused on providing users with the most validated and personalized healthcare information delivered to any device, the company’s program with IBM Watson is the first of its kind to merge artificial intelligence and deep learning with precision medicine, applicable to both consumers and providers.
Founded
2008
Headquarters
San Diego, CA, United States
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
$932.69MM
Total Funding
$127.23MM
Last Funding Round
Series E-1

Learn more about Pathway Genomics

To invest in Pathway Genomics pre-IPO

Can you invest in Pathway Genomics pre-IPO?

You can no longer invest in Pathway Genomics with Forge. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Pathway Genomics before it goes public?

You can no longer sell shares of Pathway Genomics on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Pathway Genomics shares?

Forge can no longer determine the value of Pathway Genomics shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Pathway Genomics a publicly traded company?

Pathway Genomics became a public company following its M&A on 02/14/2020 and is now a publicly traded company.

To learn more about Pathway Genomics potential IPO

Will Pathway Genomics go IPO?

Pathway Genomics became a public company following its M&A on 02/14/2020.

What is Pathway Genomics’ IPO price?

The IPO price of Pathway Genomics is not currently available.

When was Pathway Genomics founded?

Pathway Genomics was founded in 2008.

What is Pathway Genomics funding to date?

Pathway Genomics has raised $127.23MM to date.

Pathway Genomics major investors

International Business Machines

Pathway Genomics pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
01/05/2016 Series E-1 $40MM $9.50 $932.69MM International Business Machines
Price per Share
$ xx.xx
Shares Outstanding
4,210,526
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
International Business Machines
11/12/2014 Series D $35.78MM $5.00 $470MM International Business Machines
Price per Share
$ xx.xx
Shares Outstanding
7,156,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
International Business Machines
04/01/2014 Series C $36.51MM $2.13 $185MM Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
17,140,800
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
07/15/2009 Series B $11.75MM $0.62 $72.48MM Edelson Technology Partners, Founders Fund, Korea-Seoul Life Science Fund, Western Technology Investment
Price per Share
$ xx.xx
Shares Outstanding
18,813,038
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Edelson Technology Partners, Founders Fund, Korea-Seoul Life Science Fund, Western Technology Investment
07/01/2009 Series A $3.19MM $0.27 $14MM Edelson Technology Partners, Founders Fund, Western Technology Investment
Price per Share
$ xx.xx
Shares Outstanding
11,963,378
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Edelson Technology Partners, Founders Fund, Western Technology Investment

Pathway Genomics IPO news and media highlights

Prostate Biopsy Market Size, Application,Revenue, Types, Trends in Future, Scope to 2021 - TokensJournal

The Prostate Biopsy Market  report  provides valuable and unique information which is very  essential. Further it also covers key players,application and future market condition.This information is extremely useful information for new and growing  company to mark themself over the market Prostate Biopsy market to grow at a CAGR OF 12.66% during the period 2017-2021. This …

Direct-To-Consumer Genetic Testing Market with top 20 Countries data Forecast to 2022 with Global Key Companies Profile, Supply, Demand, Cost Structure and Growth Factors - TokensJournal

Direct-To-Consumer Genetic Testing Market Report cover detailed competitive outlook including the Direct-To-Consumer Genetic Testing Industry share and company profiles of the key participants operating in the global market. The Direct-To-Consumer Genetic Testing market report provides an in-depth overview of Product Specification, technology, product type and production analysis considering major factors such as Revenue, Cost, Gross and …

Direct-to-consumer Genetic Testing Market Analysis, Overview, Growth, Demand and Forecast Research Report to 2023 - BitsEther

Direct-to-consumer Genetic Testing Market Research highlights key dynamics of Global Direct-to-consumer Genetic Testing Industry sector. The potential of the Direct-to-consumer Genetic Testing Market has been investigated along with the key challenges. The current Direct-to-consumer Genetic Testing Market scenario and future prospects of the sector has also been studied. Market Report provides additional information like Sales Channel, Distributors, Traders …

Direct-To-Consumer Genetic Testing Market To See A Huge Production Growth & Business Opportunities During 2017-2021 - BittAsset

The Direct-To-Consumer Genetic Testing Market Report provides Growth history, Sales channel, Manufacturers profiled in Direct-To-Consumer Genetic Testing industry, Market share of product and scope of a Region in detail. The Market report also consists key Drivers and limiting factors affect the Direct-To-Consumer Genetic Testing Market Growth, Change in industry Trends or challenges faced by Direct-To-Consumer …
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
Generate BiomedicinesGenerate BiomedicinesNot available$ xx.xxSeries C$2.22B$11.85$399.4MM
OriginOriginNot available$ xx.xxNot available------
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
SpaceX SpaceX $603.79 +$2.52 (0.42%)High $xxx.xx
Anduril Anduril $110.97 +$4.00 (3.74%)High $xxx.xx
Databricks Databricks $197.66 +$0.01 (0.01%)High $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
Anduril Anduril $110.97 +$4.00 (3.74%)High $xxx.xx
Databricks Databricks $197.66 +$0.01 (0.01%)High $xxx.xx
Perplexity Perplexity $69.54 +$6.59 (10.47%)High $xxx.xx

Forge, your trusted partner for pre-IPO insights and Pathway Genomics data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Jul 16, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.